Colorectal cancer metastatic
Not yet recruitingOxaliplatin-based drug combination (including bevacizumab, tislelizumab, fluorouracil, folic acid) for patients with diagnosed metastatic colorectal cancer
Oxaliplatin-based drug combination (including bevacizumab, tislelizumab, fluorouracil, folic acid) for patients with diagnosed metastatic colorectal cancer
- Disease:Colorectal cancer metastatic
- Substances:BevacizumabFluorouracil+3
Norway- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
- Sponsor:Akershus University Hospital









